Silence Therapeutics plc, (LON:SLN) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced today that the US Patent and Trade Mark Office yesterday granted US patent application 15/594,349 as US Patent 9,783,802.
Silence previously reported issuance of a notice of allowance for US patent application 15/594,349 on 15 August 2017 and that relevant grant fees had been paid.
The allowed claims of US Patent 9,783,802 will provide Silence with further protection for its innovative chemical modification technology in the US. Silence believes that these newly granted claims are relevant to third-party RNAi medicines including Alnylam Pharmaceuticals’ Patisiran, which has recently demonstrated positive phase 3 trial results for the treatment of TTR-mediated Amyloidosis.
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics, commented: “This grant provides further protection for our US patent estate. We continue to believe that several third party late-stage RNAi candidates require licences under our chemical modification patent portfolio. This includes Patisiran, which is currently the most advanced RNAi drug in clinical development and has recently shown positive top line phase 3 results. We are highly encouraged by this field-validating event and excited for the prospects of patients living with ATTR.”